Stichtenoth D O, Wagner B, Frölich J C
Institute of Clinical Pharmacology, Hannover Medical School, Germany.
J Investig Med. 1998 Aug;46(6):290-6.
Nonsteroidal anti-inflammatory drugs (NSAIDs) can block renin release via inhibition of cyclooxygenase (COX). The responsible COX-isoenzyme in man is unknown. Therefore, we assessed the effects of meloxicam, a selective inhibitor of COX-2, and indomethacin, an unselective inhibitor of COX-1 and COX-2, on furosemide stimulated plasma renin activity (PRA).
In a randomized cross-over design 15 healthy female volunteers received no NSAID or meloxicam 7.5 mg/d for 6 days or indomethacin 25 mg tid for 2 days and 25 mg on the 3rd day. On the control day and on the last day of each treatment the following parameters were evaluated before and after furosemide 20 mg i.v.: PRA measured by RIA, urinary excretion of prostaglandin E2 (PGE2) assessed by gas chromatography-tandem mass spectrometry, urine volume and urinary excretion of sodium, potassium, and creatinine, and serum concentrations of sodium, potassium, and creatinine.
Furosemide led to a more than two-fold rise of PRA. Indomethacin as well as meloxicam had no significant effect on basal PRA but inhibited the furosemide-stimulated PRA increase. PGE2 excretion on the control day rose two-fold after furosemide. Meloxicam had no effect on basal PGE2 excretion, whereas indomethacin reduced this parameter by 30%. Both drugs inhibited the increase of urinary PGE2 after furosemide. No drug effects on urine flow nor on electrolytes and creatinine in serum and urine could be observed.
Meloxicam inhibited furosemide stimulated renin release, suggesting that in man COX-2 is responsible for prostaglandin synthesis mediating renin release.
非甾体抗炎药(NSAIDs)可通过抑制环氧化酶(COX)来阻断肾素释放。在人类中起作用的COX同工酶尚不清楚。因此,我们评估了COX-2的选择性抑制剂美洛昔康和COX-1与COX-2的非选择性抑制剂吲哚美辛对呋塞米刺激的血浆肾素活性(PRA)的影响。
采用随机交叉设计,15名健康女性志愿者未服用NSAIDs,或服用美洛昔康7.5mg/d,共6天,或服用吲哚美辛25mg,每日3次,共2天,第3天服用25mg。在对照日和每种治疗的最后一天,静脉注射20mg呋塞米前后评估以下参数:通过放射免疫分析法测定PRA,通过气相色谱-串联质谱法评估前列腺素E2(PGE2)的尿排泄量、尿量以及钠、钾和肌酐的尿排泄量,以及钠、钾和肌酐的血清浓度。
呋塞米导致PRA升高两倍以上。吲哚美辛和美洛昔康对基础PRA均无显著影响,但抑制了呋塞米刺激的PRA升高。对照日,呋塞米后PGE2排泄量增加两倍。美洛昔康对基础PGE2排泄量无影响,而吲哚美辛使该参数降低30%。两种药物均抑制了呋塞米后尿PGE2的增加。未观察到药物对尿流以及血清和尿液中的电解质及肌酐有影响。
美洛昔康抑制了呋塞米刺激的肾素释放,提示在人类中COX-2负责介导肾素释放的前列腺素合成。